Keybanc analyst Josh Beck downgrades Vtex (NYSE:VTEX) from Overweight to Sector Weight.
Barclays Maintains Overweight on Amedisys, Lowers Price Target to $126
Barclays analyst Sarah James maintains Amedisys (NASDAQ:AMED) with a Overweight and lowers the price target from $154 to $126.